方坚松 FANG JIANSONG 研究员
所属学院（所）：科技创新中心
导师类别： 博士生导师
科研方向：中医药学新技术新方法、中药神经药理学
硕/博士招生学院：科技创新中心
学科领域：中药学
联系方式：fangjs@gzucm.edu.cn
个人科研主页：https://www.researchgate.net/profile/Jiansong-Fang/
个人简介
方坚松，1986年出生，广州中医药大学科技创新中心研究员、北京协和医学院（清华大学医学部）药理学专业博士毕业，国家留学基金委公派克利夫兰医学中心博士后。2019年获得中国药理学会青年药理学家奖【全国共8名】，连续三年（2020-2022年度）入选美国斯坦福大学发布的全球前2%顶尖科学家榜单。长期从事基于网络医学框架下的中医药学新技术新方法研究，发展系列原创的中药网络医学研究方法及工具，服务于中医防治疾病的现代生物学基础、中药及天然产物（或老药）的靶标发现、机制阐明、以及复杂性疾病（老年痴呆及肿瘤）的转化医学等研究。目前累计以第一作者或通讯作者（含共同）在Nature子刊Nature Aging，Cell子刊Cell Chem Biol (IF=9.0)，Genome Biol (IF=17.9)，Med Res Rev (IF=12.3)，Brief Bioinform (IF=14.0)，Acta Pharm Sin B (IF=14.9)等期刊SCI论文51篇，累计一作及通讯影响因子346分，其中中科院一区文章15篇。在Nature Genetics，Cell Metabolism，Nature Communications等期刊合作发表论文40余篇。以上论文1篇入选ESI全球高被引论文，1篇被世界学术组织Faculty Opinions（原F1000 Prime）点评推荐。谷歌学术引用2650余次（H因子30）。主持国家自然基金面上项目（82074278，在研）、 国家自然青年基金项目（81603318，已结题）、广东省教育厅生物医药与健康重点领域专项等10余项课题，申请相关专利及软件著作权4项。
学术兼职
1） 学术团体委员：中国药理学学会网络药理学委员、世界中医药学会联合会网络药理学理事、中国药理学会中药与天然产物专委会青年常务委员、中国药理学会临床药理学专业委员会青年委员、中国抗癌协会肿瘤标志专业委员会肿瘤测序及大数据分析专家委员会委员、广东省药理学会神经与精神药理委员会委员。
2） 学术期刊编委会：Frontiers in Pharmacology副主编（Section: Experimental Pharmacology and Drug Discovery）及专刊客座编辑（Guest editor），Frontiers in Neuroscience及Discover Oncology客座编辑（Guest editor）；英文期刊Pharmacological Research: Modern Chinese Medicine编委。兼任Nature communications, Clinical and translational medicine, Signal Transduction and Targeted Therapy, Pharmacological research, Phytomedicine, PLOS Computational Biology, Food & function等50余个SCI期刊审稿专家。
3） 基金评审及SCI期刊审稿专家：国家自然基金评审专家。Nature Communications, Clinical and translational medicine, Signal Transduction and Targeted Therapy, Pharmacological Research, Phytomedicine, Journal of Ethnopharmacology, Food & Function, Journal of Functional Foods, Journal of Alzheimer's Disease等30余个SCI期刊审稿专家。
个人荣誉
国家一级学会中国药理学会青年药理学家（2019年，全国共8名）；
连续三年入选斯坦福大学发布的全球前2%顶尖科学家榜单（2020-2022）
近期受邀学术报告
1） 第十八次全国临床药理学学术会议青年学术论坛学术报告（2022年12月）；
2） 上海中医药大学“集智创新”学术沙龙学术报告（2022年11月）；
3） 天津中医药大学抗肿瘤青年专家研讨会学术报告（2022年8月）；
4） 天津药理学会主办的网络药理学赋能医药健康“产学研用”多学科研讨学术沙龙学术报告（2022年4月）；
5） 杜冠华教授执教五十周年学术研讨会学术报告（2022年3月）
近五年代表作（第一及通讯作者）
(1) Fang J#, Zhang P#, Zhou Y#, Chiang WC#, Tan J, Hou Y, Stauffer S, Li L, Pieper AA, Cummings J, Cheng F*. Endophenotype-based discovery and population-based validation of Sildenafil in reducing the incidence of Alzheimer’s disease. Nat Aging. 2021;1(12): 1175-1188 （Nature子刊）.
(2) Fang J, Zhang P, Wang Q, Chiang CW, Zhou Y, Hou Y, Xu J, Chen R, Zhang B, Lewis SJ, Leverenz JB, Pieper AA, Li B*, Li L*, Cummings J, Cheng F*. Artifcial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):7. (IF: 8.82，中科院一区)
(3) Fang J, Wang D, Fan X. Developing a taxonomy for colorectal cancer. Elife. 2022 Nov 11;11:e84025. (IF: 8.71，中科院一区)
(4) Wang Q, Su S, et al, Fang J*. Network Proximity-based computational pipeline identifies drug candidates for different pathological stage of Alzheimer's disease. Comput Struct Biotechnol J 2023 (doi: 10.1016/j.csbj.2023.02.041, Just accepted, IF: 6.16)
(5) Zhao J, Li F, Wu Q, Cheng Y, Liang G, Wang X, Fang S, Wang Q, Fan X*, Fang J*. Association between trichlorophenols and neurodegenerative diseases: A cross-sectional study from NHANES 2003-2010. Chemosphere. 2022 Jul 20:135743. (IF: 8.94)
(6) Song L, Wu Q, Fu X, Wang W, Dai Z, Gu Y, Zhuo Y, Fang S, Zhao W, Wang X, Wang Q*, Fang J*. In Silico Identification and Mechanism Exploration of Active Ingredients against Stroke from An-Gong-Niu-Huang-Wan (AGNHW) Formula. Oxid Med Cell Longev. 2022;5218993. (IF: 7.31)
(7) Liu Z, Du J, Lin Z, Li Z, Liu B, Cui Z, Fang J*, Xie L*. DenovoProfiling: a webserver for de novo generated molecule library profiling. Comput Struct Biotechnol J 2022 Aug 2;20:4082-4097. (IF: 6.16)
(8) Dai Z, Pang X, Fang J*.Editorial: Data mining and network-driven analysis: Drug discovery and mechanism exploration by targeting vascular dysfunction. Front. Pharmacol. 2022;13:1099854 (IF: 5.99)
(9) Wang X#, Fan X#, Wu Q#, Liu J, Yu X*, Wang J*, Fang J* (方坚松). Uric acid predicts recovery of left ventricular function and adverse events in heart failure with reduced ejection fraction: potential mechanistic insight from network analyses. Front Cardiovasc Med. 2022;9:853870 (IF: 5.85，三区)
(10) Dai Z, Hu T, Su S, Liu J, Ma Y, Fang S, Wang Q, Mo Y*, Pan H* and Fang J*. Comparative Metabolomics Analysis Reveals Key Metabolic Mechanisms and Protein Biomarkers in Alzheimer’s Disease. Front. Pharmacol. 2022;13:904857（IF:5.99）
(11) Mo Z, Zeng Z, Liu Y, Zeng L, Fang J*, and Ma Y*. Activation of Wnt/Beta-Catenin Signaling Pathway as a Promising Therapeutic Candidate for Cerebral Ischemia/Reperfusion Injury. Front. Pharmacol. 2022;13:914537. (IF: 5.99)
(12) Zhuo Y*, Li M, Jiang Q, Ke H, Liang Q, Zeng L*, Fang J*. Evolving Roles of Natural Terpenoids from Traditional Chinese Medicine in the Treatment of Osteoporosis. Front Endocrinol 2022;13: 901545. (IF: 6.06，二区)
(13) Cai C, Xu L, Fang J, Dai Z, Wu Q, Liu X, Wang Q, Fang J*, Liu AL*, Du GH*. In Silico Prediction and Bioactivity Evaluation of Chemical Ingredients Against Influenza A Virus From Isatis tinctoria L. Front Pharmacol. 2021;12:755396. (IF: 5.99)
(14) Zhou Y#, Zhao J#, Fang J#, Martin W, Li L, Nussinov R, Chan TA, Eng C, and Cheng F*. My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. Genome Biol 2021;22(1):53. (IF:17.91，中科院一区)
(15) Zhou Y#, Fang J#, Bekris LM, Kim YH, Pieper AA, Leverenz JB, Cummings J, Cheng F*. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery. Alzheimers Res Ther. 2021;13(1):24. (IF: 8.82，中科院一区)
(16) Li D#, Cai C#, Liao Y#, Wu Q, Ke H, Guo P, Wang Q, Ding B, Fang J*, Fang S*. Systems Pharmacology Approach Uncovers the Therapeutic Mechanism of Medicarpin against Scopolamine-induced Memory Loss. Phytomedicine. 2021;91:153662. (IF: 6.66，中科院一区)
(17) Fang J#, Wu Q#, Ye F#, Cai C, Xu L, Gu Y, Wang Q, Liu A-L*, Tan W*, Du G-H*. Network-Based Identification and Experimental Validation of Drug Candidates Toward SARS-CoV-2 via Targeting Virus–Host Interactome. Front. Genet. 2021; 12:728960. (IF:4.77，三区)
(18) Cai C#, Wu Q#, Hong H, He L, Liu Z, Gu Y, Zhang S, Wang Q, Fan X*, Fang J*. In silico identifcation of natural products from traditional Chinese medicine for cancer
immunotherapy. Sci Rep . 2021;11(1):3332. (IF:5.00)
(19) Fan X#, Fang J#, Wu X#, Poulsen K, Miyata T, Kim A, Yu L, Wang X, Zhang X, Zhang K, Han Q*, Liu Z*. Effect of HIV infection on pre- and post-liver transplant mortality in patients with organ failure. HIV Med. 2021;22(8):662-673. (IF:3.09，四区)
(20) Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB, Cummings J, Cheng F*. Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. Med Res Rev. 2020; 40(6):2386-2426. (IF:12.39，中科院一区)
(21) Hong H#, Mo Y#, Li D#, Xu Z, Liao Y, Yin P, Liu X, Xia Y, Fang J*, Wang Q* and Fang S*. Aberrant Expression Profiles of lncRNAs and Their Associated Nearby Coding Genes in the Hippocampus of the SAMP8 Mouse Model with AD. Mol Ther Nucleic Acids. 2020; 20:140-154. （IF:10.18，中科院一区）
(22) Huang Y, Zhang Y, Wan T, Mei Y, Wang Z, Xue J, Luo Y, Li M, Fang S, Pan H, Wang Q*, Fang J*. Systems pharmacology approach uncovers Ligustilide attenuates experimental colitis in mice by inhibiting PPARγ-mediated inflammation pathways. Cell Biol Toxicol. 2021 Feb;37(1):113-128. （IF:6.82，中科院小类一区）
(23) Wu Q, Fan X, Hong H, Gu Y, Liu Z, Fang S, Wang Q, Cai C, Fang J*. Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective. Food Chem Toxicol. 2020;145:111767. （IF:5.57，二区）
(24) Li J, Fang J*, Qin X*, Gao L*. Metabolomics Profiling Reveals the Mechanism of Caffeic Acid in Extending Lifespan in Drosophila melanogaster. Food Funct. 2020. 11(9):8202-8213. （IF: 5.40，中科院一区）
(25) Luo Y#, Li D#, Liao Y#, Cai C, Wu Q, Ke H, Liu X, Li H, Hong H, Xu Y, Wang Q*, Fang J*, Fang S*. Systems Pharmacology Approach to Investigate the Mechanism of Kai-Xin-San in Alzheimer’s disease. Front. Pharmacol. 2020; 11: 381. （IF: 5.99）
(26) Liu Z#, Cai C#, Du J#, Liu B, Cui L, Fan X, Fang J*, Xie L*.TCMIO: A Comprehensive Database of Traditional Chinese Medicine on Immuno-Oncology. Front. Pharmacol. 2020; 11: 439. （IF: 5.99）
(27) Gao L, Cao M, Li JQ, Qin XM, Fang J*. Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine. Curr Pharm Des. 2020 Nov 12. （IF:3.12，四区）
(28) Wu Q, Chen Y, Gu Y, Fang S, Li W, Wang Q*, Fang J*, Cai C*.Systems pharmacology-based approach to investigate the mechanisms of Danggui-Shaoyao-san prescription for treatment of Alzheimer's disease. BMC Complement Med Ther. 2020 Sep 18;20(1):282.（IF:3.66，二区小类）
(29) Fang J, Cai C, Chai Y, Zhou J, Huang Y, Gao L, Wang Q, Cheng F*. Quantitative and systems pharmacology 4. Network-based analysis of drug pleiotropy on coronary artery disease. Eur J Med Chem 2019; 161:192-204.（IF:7.09，中科院一区）
(30) Huang Y, Fang J*, Lu W*, Wang Z, Wang Q, Hou Y, Jiang X, Reizes O, Lathia J, Nussinov R, Eng C, Cheng F*. A systems pharmacology approach uncovers wogonoside as a novel angiogenesis inhibitor of triple-negative breast cancer by targeting Hedgehog signaling, Cell Chem Biol. 2019;26(8):1143-1158.e6.（IF: 9.04，中科院一区）
(31) Guo P, Cai C, Wu X, Fan , Huang W, Zhang Y*, Fang J*. An Insight Into the Molecular Mechanism of Berberine Towards Multiple Cancer Types Through Systems Pharmacology. Front Pharmacol 2019;10:857.（IF: 5.99）
(32) Cai C, Guo P, Zhou Y, Zhou J, Wang Q, Zhang F, Fang J*, Cheng F*. Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity. J Chem Inf Model 2019;59(3):1073-1084.（IF:6.16，二区）
(33) Wu Q#, Cai C#, Guo P, Chen M, Wu X, Zhou J, Luo Y, Zou Y, Liu AL, Wang Q, Kuang Z*, Fang J*. In Silico Identification and Mechanism Exploration of Hepatotoxic Ingredients in Traditional Chinese Medicine. Front Pharmacol 2019;10:458.（IF: 5.99）
(34) Wu Q, Ke H, Li D, Wang Q, Fang J*, Zhou J*. Recent Progress in Machine Learning-based Prediction of Peptide Activity for Drug Discovery. Curr Top Med Chem 2019;19(1):4-16.（IF:3.57，四区）
(35) Wang L#, Fang J#, Jiang H, Wang Q, Xue S, Li Z, Liu R. 7-pyrrolidinethoxy-4'-methoxyisoflavone prevents amyloid β–induced injury by regulating histamine H3 receptor-mediated cAMP/CREB and AKT/GSK3β pathways. Frontiers in neuroscience 2019; 13, 334（IF:5.15，二区）
(36) Fang J, Liu C, Wang Q, Lin P, and Cheng F*. In silico polypharmacology of natural products. Brief Bioinform, 2018;19(6):1153-1171.（IF:13.99，中科院小类一区）
(37) Cai C, Fang J*, Guo P, Wang Q, Hong H, Moslehi J, Cheng F*. In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers. J Chem Inf Model 2018;58(5):943-956.（IF: 6.16）
(38) Cai H, Luo Y, Yan X, Fang J*, Wang Q*, Xu J*. The mechanisms of Bushen-Yizhi formula as a therapeutic agent against Alzheimer’s disease. Sci Rep 2018;8(1):3104. (IF:5.00)
(39) Luo YX, Wang XY, Huang YJ, Wang Q*, Fang J*. Systems pharmacology-based investigation of Sanwei Ganjiang Prescription: related mechanisms in liver injury. Chin J Nat Med. 2018;16(10):756-765.（IF:3.89，小类二区）
(40) Fang J, Gao L, Wang Q*, Cheng F*. Quantitative and systems pharmacology 3. Network-based identification of new targets for natural products enables potential uses in aging-associated disorders. Front Pharmacol. 2017; 8: 747.（IF: 5.99）
(41) Fang J#, Wu Z#, Cai C, Wang Q, Tang Y*, Cheng F*. Quantitative and systems pharmacology. 1. In silico prediction of drug-target interactions of natural products enables new targeted cancer therapy. J Chem Inf Model. 2017; 57(11): 2657-2671.（IF: 6.16）
(42) Fang J, Wang L, Wu T, Yang C, Gao L, Cai H, Liu J, Fang S, Chen Y, Tan W*, Wang Q*. Network pharmacology-based study on the mechanism of action for herbal medicines in Alzheimer treatment. J Ethnopharmacol. 2017; 196:281-292（IF:5.20，中科院小类一区）
(43) Fang J, Cai C, Wang Q, Ping L, Zhao Z*, and Cheng F*. Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes. CPT Pharmacometrics Syst Pharmacol. 2017; 6(3):177-187. （IF:4.34，小类二区）
(44) Fang J, Wang L, Li Y, Lian W, Pang X, Wang H, Yuan D, Wang Q, Liu AL*, Du GH*. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer’s disease. PLoS one 2017; 12 (5), e0178347.（IF:3.75，三区）
项目主持
1） 国家自然面上项目（82074278）：基于网络距离法探讨“肾-髓-脑”理论调控内质网应激防治AD及补肾益智方干预的机制，2021.01-2024.12，55万，主持（在研）；
2） 国家自然青年基金（81603318）：基于网络多靶标探讨补肾益智方抗AD药效物质基础及作用机制，2017.01-2019.12，17万，主持（已结题）；
3） 广东省教育厅生物医药与健康重点领域专项：基于网络距离法的中药肝毒性预测及其毒理机制研究(No. 2021ZDZX2001) ，2022.01-2024.12，30万，主持（在研）；
4） 广东省教育厅普通高校特色创新类项目：基于系统药理学的中药有效成分药物靶标识别及其功能验证研究，2017.04-2018.12，10万，主持（已结题）；
5） 双一流学科协同创新团队培育项目（2021xk68）：中药网络医学发展与应用，2021.06-2024.05，60万，主持（在研）；
6） 广州中医药大学青年英才项目，2020-2021，10万，主持（已结题）；
7） 双一流大学特色培育项目（xkp2019005） ：基于系统药理学的抗肿瘤活性天然产物发现，2019.04-2020.12，40万，主持（已结题）；
8） 高水平大学青年科研培育项目（2019QNPY05）： 基于网络距离邻近法预测中药天然产物抗三阴性乳腺癌活性及作用机制研究，2019.05-2021.12，25万，主持（已结题）。
9）高水平大学面上项目（A1-AFD018171Z11027）：中草药-靶标数据库构建及其应用研究。2017-2018，20万，主持（已结题）。
